X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-10 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $100.21 | -7,071 | 118,466 | -6% | -$708,576 | |||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $23.39 | -7,455 | 74,266 | -9% | -$174,372 | ||||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $23.39 | -1,236 | 17,795 | -6% | -$28,910 | ||||||
2026-02-11 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $23.39 | -1,671 | 16,938 | -9% | -$39,085 | ||||||
2026-02-10 | MPLT | Maplight Therapeutics, Inc. | Garnett Timothy John | Dir | P - Purchase | $17.89 | +14,124 | 63,649 | +29% | +$252,678 | ||||||
| M | 2026-02-10 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.12 | -6,863 | 383,042 | -2% | -$124,329 | |||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $460.43 | -466 | 51,436 | -1% | -$214,560 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $460.43 | -2,021 | 12,914 | -14% | -$930,529 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $460.43 | -1,925 | 20,819 | -8% | -$886,328 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $460.43 | -1,751 | 22,046 | -7% | -$806,213 | ||||||
2026-02-11 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $460.43 | -1,376 | 10,127 | -12% | -$633,552 | ||||||
| M | 2026-02-10 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $71.86 | -80,000 | 5,382,909 | -1% | -$5,748,666 | |||||
| DM | 2026-02-10 | KNSA | Kiniksa Pharmaceuticals International, Plc | Quart Barry D | Dir | S - Sale+OE | $45.00 | -2,800 | 12,546 | -18% | -$126,000 | |||||
2026-02-10 | SDGR | Schrodinger, Inc. | Tran Yvonne | EVP, CLO, CPO | S - Sale | $13.80 | -776 | 22,859 | -3% | -$10,705 | ||||||
2026-02-10 | SDGR | Schrodinger, Inc. | Lorton Kenneth Patrick | EVP, CTO, COO, Software | S - Sale | $13.73 | -925 | 52,651 | -2% | -$12,704 | ||||||
2026-02-10 | SDGR | Schrodinger, Inc. | Herman Jenny | CAO | S - Sale | $13.79 | -752 | 26,597 | -3% | -$10,370 | ||||||
2026-02-10 | SGMT | Sagimet Biosciences Inc. | Happel David | Pres, CEO | S - Sale | $5.36 | -12,101 | 677,621 | -2% | -$64,865 | ||||||
2026-02-10 | SGMT | Sagimet Biosciences Inc. | Chauche Thierry | CFO | S - Sale | $5.36 | -1,312 | 15,688 | -8% | -$7,033 | ||||||
2026-02-10 | SGMT | Sagimet Biosciences Inc. | Martins Eduardo Bruno | Chief Medical Officer | S - Sale | $5.36 | -3,640 | 103,296 | -3% | -$19,511 | ||||||
2026-02-10 | SGMT | Sagimet Biosciences Inc. | Rozek Elizabeth | Chief Legal, Admin. Officer | S - Sale | $5.36 | -2,622 | 190,959 | -1% | -$14,054 | ||||||
2026-02-12 | MRK | Merck & Co., Inc. | Guindo Chirfi | CMO | S - Sale | $121.46 | -10,000 | 60,615 | -14% | -$1,214,562 | ||||||
| D | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale+OE | $23.12 | -109 | 19,031 | -1% | -$2,520 | |||||
| D | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale+OE | $23.12 | -147 | 18,609 | -1% | -$3,399 | |||||
| D | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Moran Kyle | CFO | S - Sale+OE | $13.45 | -3,588 | 134,385 | -3% | -$48,259 | |||||
| D | 2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale+OE | $23.12 | -438 | 81,721 | -1% | -$10,127 | |||||
| D | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale+OE | $13.45 | -10,480 | 275,520 | -4% | -$140,956 | |||||
| D | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $13.45 | -1,883 | 61,867 | -3% | -$25,326 | |||||
2026-02-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $23.12 | -254 | 15,637 | -2% | -$5,872 | ||||||
| D | 2026-02-09 | WVE | Wave Life Sciences Ltd. | Vargeese Chandra | See Remarks | S - Sale+OE | $13.45 | -3,228 | 408,246 | -1% | -$43,417 | |||||
| D | 2026-02-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $30.21 | -2,171 | 50,437 | -4% | -$65,586 | |||||
| M | 2026-02-10 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $51.77 | -72,198 | 67,600 | -52% | -$3,737,711 | |||||
2026-02-09 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | See Remarks | S - Sale | $13.51 | -1,230 | 19,385 | -6% | -$16,617 | ||||||
| D | 2026-02-09 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $26.47 | -339,441 | 18,836,547 | -2% | -$8,985,003 | |||||
| D | 2026-02-09 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $147.79 | -13,396 | 585,609 | -2% | -$1,979,764 | |||||
| D | 2026-02-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $43.28 | -17,845 | 12,086 | -60% | -$772,254 | |||||
2026-02-09 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $5.22 | +3,955 | 135,508 | +3% | +$20,651 | ||||||
| D | 2026-02-09 | REGN | Regeneron Pharmaceuticals, Inc. | Pitofsky Jason | SVP Controller | S - Sale+OE | $778.52 | -2,036 | 4,482 | -31% | -$1,585,058 | |||||
2026-02-09 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $778.53 | -100 | 17,803 | -1% | -$77,853 | ||||||
| D | 2026-02-03 | URGN | Urogen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $19.69 | -7,479 | 55,588 | -12% | -$147,262 | |||||
| M | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | Bruns Ingmar | Chief Medical Officer | S - Sale | $2.43 | -3,297 | 33,332 | -9% | -$7,998 | |||||
| M | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | Vultaggio Vincent | PAO, PFO | S - Sale | $2.43 | -40,224 | 146,506 | -22% | -$97,557 | |||||
| M | 2026-02-06 | ZNTL | Zentalis Pharmaceuticals, Inc. | Eastland Julia Marie | CEO, Pres | S - Sale | $2.43 | -8,755 | 79,133 | -10% | -$21,239 | |||||
| D | 2026-02-06 | CING | Cingulate Inc. | Werth Peter J. | Dir | P - Purchase | $5.04 | +19,455 | 117,541 | +20% | +$98,053 | |||||
| D | 2026-02-06 | CING | Cingulate Inc. | Callahan Jennifer L. | SVP, CFO | P - Purchase | $5.04 | +4,864 | 5,059 | >999% | +$24,515 | |||||
| D | 2026-02-06 | CING | Cingulate Inc. | Schaffer Shane J. | CEO | P - Purchase | $5.04 | +6,809 | 10,348 | +192% | +$34,317 | |||||
| D | 2026-02-06 | CING | Cingulate Inc. | Brams Matthew | EVP, Chief Medical Officer | P - Purchase | $5.04 | +1,946 | 4,656 | +72% | +$9,808 | |||||
2026-02-06 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $29.04 | -5,000 | 740,188 | -1% | -$145,219 | ||||||
| D | 2026-02-09 | ACAD | Acadia Pharmaceuticals Inc | Rhodes Jennifer J | EVP, GC, SEC | S - Sale+OE | $23.38 | -6,950 | 7,609 | -48% | -$162,491 | |||||
2026-02-06 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $85.79 | -29,430 | 254,497 | -10% | -$2,524,820 | ||||||
| D | 2026-02-09 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $8.56 | -14,625 | 387,225 | -4% | -$125,186 | |||||
| D | 2026-02-09 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $474.65 | -22,500 | 2,648 | -89% | -$10,679,686 | |||||
2026-02-10 | MRK | Merck & Co., Inc. | Li Dean Y | EVP, Pres, MRL | S - Sale | $117.52 | -10,235 | 92,035 | -10% | -$1,202,844 | ||||||
2026-02-09 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale | $21.03 | -17,159 | 491,690 | -3% | -$360,819 | ||||||
2026-02-09 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $21.03 | -3,410 | 140,429 | -2% | -$71,705 | ||||||
2026-02-06 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale | $2.36 | -87,917 | 1,012,091 | -8% | -$207,484 | ||||||
2026-02-06 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | COO | S - Sale | $2.36 | -18,652 | 742,506 | -2% | -$44,019 | ||||||
2026-02-09 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale | $16.66 | -14,261 | 42,749 | -25% | -$237,618 | ||||||
| M | 2026-02-04 | MANE | Veradermics, Inc | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $37.30 | +282,674 | 520,453 | +119% | +$10,542,478 | |||||
2026-02-06 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $2.70 | +300 | 70,107 | 0% | +$810 | ||||||
| D | 2026-02-05 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $48.38 | -110,842 | 139,798 | -44% | -$5,362,103 | |||||
2026-02-06 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $0.95 | +50,000 | 1,915,651 | +3% | +$47,280 | ||||||
2026-02-09 | MRK | Merck & Co., Inc. | Guindo Chirfi | CMO | S - Sale | $118.41 | -10,000 | 70,615 | -12% | -$1,184,101 | ||||||
| D | 2026-02-09 | MRK | Merck & Co., Inc. | Zachary Jennifer | EVP, GC | S - Sale+OE | $119.15 | -121,573 | 68,916 | -64% | -$14,485,690 | |||||
| M | 2026-02-04 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale | $106.03 | -6,628 | 125,537 | -5% | -$702,744 | |||||
| D | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale+OE | $20.62 | -7,412 | 508,849 | -1% | -$152,835 | |||||
| D | 2026-02-06 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale+OE | $20.62 | -2,082 | 143,839 | -1% | -$42,931 | |||||
| D | 2026-02-04 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $349.52 | -1,660 | 223,106 | -1% | -$580,197 | |||||
| D | 2026-02-06 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $83.68 | -20,000 | 7,825 | -72% | -$1,673,600 | |||||
| D | 2026-02-06 | MRK | Merck & Co., Inc. | Williams David Michael | EVP,Chief Info, Digital Office | S - Sale+OE | $121.91 | -5,000 | 30,838 | -14% | -$609,525 | |||||
2026-02-05 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $152.44 | -869 | 83,243 | -1% | -$132,470 | ||||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Smart Dalton E. III | SVP Fin. - Global Controller | S - Sale+OE | $119.68 | -6,400 | 8,205 | -44% | -$765,920 | |||||
2026-02-06 | MRK | Merck & Co., Inc. | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $121.87 | -15,000 | 21,197 | -41% | -$1,827,992 | ||||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Litchfield Caroline | EVP, CFO | S - Sale+OE | $119.61 | -41,997 | 90,192 | -32% | -$5,023,312 | |||||
| D | 2026-02-04 | MRK | Merck & Co., Inc. | Li Dean Y | EVP, Pres, MRL | S - Sale+OE | $118.77 | -15,087 | 102,270 | -13% | -$1,791,824 | |||||
2026-02-05 | MRK | Merck & Co., Inc. | Guindo Chirfi | CMO | S - Sale | $121.88 | -20,000 | 80,615 | -20% | -$2,437,676 | ||||||
2026-02-06 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale | $120.92 | -37,685 | 160,174 | -19% | -$4,557,025 | ||||||
2026-02-04 | MRK | Merck & Co., Inc. | Davis Robert M | COB, CEO, Pres | S - Sale | $118.05 | -47,434 | 443,602 | -10% | -$5,599,327 | ||||||
2026-02-04 | ABT | Abbott Laboratories | Starks Daniel J | Dir | P - Purchase | $108.73 | +10,000 | 6,739,075 | 0% | +$1,087,331 | ||||||
| D | 2026-02-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $61.93 | -15,000 | 50,440 | -23% | -$928,950 | |||||
| DM | 2026-02-03 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $41.39 | -13,180 | 65,640 | -17% | -$545,473 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Coric Vlad | Dir | P - Purchase | $17.00 | +117,646 | 449,337 | +35% | +$1,999,982 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Childs John W | Dir | P - Purchase | $17.00 | +294,117 | 2,202,006 | +15% | +$4,999,989 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-05 | MANE | Veradermics, Inc | Enright Patrick G | Dir, 10% | P - Purchase | $17.00 | +1,075,000 | 2,053,474 | +110% | +$18,275,000 | |||||
| D | 2026-02-03 | PMN | Promis Neurosciences Inc. | Abg Management Ltd. | 10% | P - Purchase | $12.13 | +700,741 | 943,090 | +289% | +$8,499,988 | |||||
| D | 2026-02-03 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $40.87 | -20,000 | 1,235 | -94% | -$817,334 | |||||
| D | 2026-02-05 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $483.25 | -8,300 | 36,781 | -18% | -$4,010,940 | |||||
2026-02-03 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $14.94 | -4,170 | 162,894 | -2% | -$62,305 | ||||||
2026-02-04 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $6.69 | -970 | 612,919 | 0% | -$6,489 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $32.21 | -1,779 | 105,706 | -2% | -$57,295 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $32.19 | -1,745 | 111,226 | -2% | -$56,168 | ||||||
2026-02-04 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale | $32.18 | -2,994 | 105,211 | -3% | -$96,359 | ||||||
2026-02-03 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.10 | -5,559 | 550,000 | -1% | -$22,792 | ||||||
| DM | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Keutzer Timothy | COO | S - Sale+OE | $2.17 | -46,586 | 761,158 | -6% | -$101,175 | |||||
| D | 2026-02-02 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale+OE | $2.20 | -18,442 | 1,100,008 | -2% | -$40,572 | |||||
2026-02-02 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $32.80 | -15,000 | 657,540 | -2% | -$492,045 | ||||||
| M | 2026-02-02 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.02 | -7,040 | 389,905 | -2% | -$126,861 | |||||
2026-02-02 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $25.28 | -40,638 | 110,003 | -27% | -$1,027,293 | ||||||
| M | 2026-02-02 | ZNTL | Zentalis Pharmaceuticals, Inc. | Vultaggio Vincent | PAO, PFO | S - Sale | $2.54 | -3,096 | 186,730 | -2% | -$7,875 | |||||
| M | 2026-02-02 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $8.82 | -11,490 | 377,802 | -3% | -$101,398 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |